



## Request to marketing authorisation holders to send the approved version of the risk management plan

date: 07/06/2022

**The Vigilance Division of the FAMHP requests marketing authorisation holders to send the approved version of the risk management plan for medicinal products for human use with a national marketing authorisation.**

In order to have a better overview of the approved risk management plans (RMP), the FAMHP asks marketing authorisation holders to send the most recently approved risk management plan and any subsequent changes to [vig@fagg-afmps.be](mailto:vig@fagg-afmps.be).

From now on, the email sent to marketing authorisation holders upon the closing of a variation procedure will also ask that when the risk management plan is updated, the approved version of that plan in PDF format, as well as any questions, be sent to [vig@fagg-afmps.be](mailto:vig@fagg-afmps.be).

[Back](#)

Last updated on 07/06/2022